Recro's Dex-IN meets in Phase II pain study

Recro Pharma Inc. (NASDAQ:REPH) gained $0.65 to $16.58 after it said Dex-IN met the primary endpoint of a Phase II trial to treat acute pain in patients undergoing bunionectomy.

The intranasal formulation of dexmedetomidine, an adrenergic receptor alpha 2 ( ADRA2) agonist, significantly reduced summed pain intensity vs. placebo over 48 hours beginning one day after surgery. One subject in the 168-patient study experienced a severe adverse event of hypotension. ...